BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...BioCentury’s roundup of translational news By Danielle Golovin, Staff Writer Philogen immunocytokine for brain cancerUniversity of...
...reported data from the first three patients with grade III/IV glioblastoma in a Phase I/II trial of Philogen S.p.A.’s...
...– Tumor necrosis factor Danielle Golovin Fibromun (L19-TNF) ALPN-101 177Lu-satetraxetan-lilotomab, Betalutin (177Lu-DOTA-HH1) MP0420 University of Zurich Swiss Federal Institute of Technology Zurich (ETHZ) Philogen S.p.A. Novartis...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...and effector T cell surfaces. That includes Philogen S.p.A....
...Therapeutics Inc. Ascendis Pharma A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics Corp. Philogen S.p.A. Xilio...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...doing option deals,” he said. For example, Novartis signed a collaboration and licensed agreement with Philogen S.p.A....
BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

...$69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen...
...own sales force. The funds will push the company's two lead candidates through to registration, Philogen S.p.A....
...Phase III study to treat metastatic soft tissue sarcoma. The Neri family has been among Philogen's...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...pegylation to improve IL-2’s safety, other companies have used targeting domains and engineered receptor specificity. Philogen S.p.A....
...below. (A) In the Phase III study, Darleukin is being given as a component of Philogen’s...
...Sources: BCIQ: BioCentury Online Intelligence; ClinicalTrials.gov; company web sites Company Product Description Lead indication Status Philogen S.p.A....
BioCentury | Jul 10, 2017
Distillery Therapeutics

Cancer

...with vehicle. Next steps could include testing the fusion protein in additional models of cancer. Philogen S.p.A....
BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

...clinic that aim to localize the effects of IL-2 to tumors. The most advanced are Philogen S.p.A....
...distance from the tumor, which should allow treatment of both primary tumors and metastatic sites. Philogen...
...and Institutions Mentioned Albert Einstein College of Medicine, Bronx, N.Y. Cue Biopharma Inc., Cambridge, Mass. Philogen S.p.A....
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

...the combination of IL-2/antibody complex and checkpoint inhibitors in a mouse model of metastatic melanoma. Philogen S.p.A....
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...immune-related toxicities. Source: BCIQ: BioCentury Online Intelligence; Courier Therapeutics Inc. Company Product Description Indication(s) Status Philogen S.p.A....
...the therapeutic window,” said Gladstone. He said that therapies already in the clinic, such as Philogen...
...opposite effect of OMCP-mutIL-2: selectively activating Tregs over NK or effector T cells. Dario Neri, Philogen’s...
BioCentury | Aug 22, 2016
Company News

Philogen, J&J deal

...Inc. subsidiary partnered to discover and develop immunomodulatory therapeutics. The companies declined to disclose details. Philogen S.p.A....
Items per page:
1 - 10 of 44
BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...BioCentury’s roundup of translational news By Danielle Golovin, Staff Writer Philogen immunocytokine for brain cancerUniversity of...
...reported data from the first three patients with grade III/IV glioblastoma in a Phase I/II trial of Philogen S.p.A.’s...
...– Tumor necrosis factor Danielle Golovin Fibromun (L19-TNF) ALPN-101 177Lu-satetraxetan-lilotomab, Betalutin (177Lu-DOTA-HH1) MP0420 University of Zurich Swiss Federal Institute of Technology Zurich (ETHZ) Philogen S.p.A. Novartis...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...and effector T cell surfaces. That includes Philogen S.p.A....
...Therapeutics Inc. Ascendis Pharma A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics Corp. Philogen S.p.A. Xilio...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...doing option deals,” he said. For example, Novartis signed a collaboration and licensed agreement with Philogen S.p.A....
BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

...$69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen...
...own sales force. The funds will push the company's two lead candidates through to registration, Philogen S.p.A....
...Phase III study to treat metastatic soft tissue sarcoma. The Neri family has been among Philogen's...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...pegylation to improve IL-2’s safety, other companies have used targeting domains and engineered receptor specificity. Philogen S.p.A....
...below. (A) In the Phase III study, Darleukin is being given as a component of Philogen’s...
...Sources: BCIQ: BioCentury Online Intelligence; ClinicalTrials.gov; company web sites Company Product Description Lead indication Status Philogen S.p.A....
BioCentury | Jul 10, 2017
Distillery Therapeutics

Cancer

...with vehicle. Next steps could include testing the fusion protein in additional models of cancer. Philogen S.p.A....
BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

...clinic that aim to localize the effects of IL-2 to tumors. The most advanced are Philogen S.p.A....
...distance from the tumor, which should allow treatment of both primary tumors and metastatic sites. Philogen...
...and Institutions Mentioned Albert Einstein College of Medicine, Bronx, N.Y. Cue Biopharma Inc., Cambridge, Mass. Philogen S.p.A....
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

...the combination of IL-2/antibody complex and checkpoint inhibitors in a mouse model of metastatic melanoma. Philogen S.p.A....
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...immune-related toxicities. Source: BCIQ: BioCentury Online Intelligence; Courier Therapeutics Inc. Company Product Description Indication(s) Status Philogen S.p.A....
...the therapeutic window,” said Gladstone. He said that therapies already in the clinic, such as Philogen...
...opposite effect of OMCP-mutIL-2: selectively activating Tregs over NK or effector T cells. Dario Neri, Philogen’s...
BioCentury | Aug 22, 2016
Company News

Philogen, J&J deal

...Inc. subsidiary partnered to discover and develop immunomodulatory therapeutics. The companies declined to disclose details. Philogen S.p.A....
Items per page:
1 - 10 of 44